Pharmaceutical organizations are under increasing pressure to make faster, smarter R&D decisions in an environment defined by complexity, uncertainty, and constant change. Making the environment even more vulnerable – and volatile – is the looming “patent cliff” for some of the world’s best-selling drugs, which some analysts predict will trigger up to $350 billion in losses by 2032, according to CNBC.
Yet even as the stakes rise, many teams are working with an incomplete picture — strong internal data, but limited visibility into the external market intelligence needed to guide better decisions.
Many organizations rely solely on internal data and insular analysis, creating a myopic view of their portfolio that lacks the external market signals and benchmarks needed to make high-stakes investment decisions with confidence. The result is a critical blind spot: the external market and competitive dynamics essential for complete strategic visibility.
That’s why we’re excited to announce a new strategic partnership between Planview and Ozmosi.
Planview and Ozmosi: What It Means for Your Portfolio
Founded in 2013, Ozmosi was built on the belief that today’s healthcare data can be better accessed, understood, and leveraged. The company delivers on its vision by providing deeply curated pharmaceutical and clinical trial intelligence, aggregating data across global clinical trials, drug development programs, and regulatory activity into a structured, machine-readable format.
Through this partnership, Ozmosi’s intelligence integrates directly with the Planview platform, enabling organizations to incorporate real-world clinical and market signals into their portfolio analysis. Now teams can move beyond evaluating pipelines in isolation, replacing internal assumptions with a grounded view of the competitive and regulatory landscape.
This allows decision-makers to answer critical questions like these with greater confidence:
- Should changes in competitive dynamics prompt us to reconsider whether we’re investing in the right opportunities?
- What gaps and white space exist in our pipeline, and how can we best address them?
- Are we validating our business case assumptions against external pipeline intelligence?
In other words, the Planview platform evolves from a powerful internal planning solution into a more complete decision environment that reflects both internal priorities and external industry data. Combined with AnviTM, Planview’s AI for connected work, teams can model scenarios, validate assumptions, and make portfolio decisions with greater speed and confidence.
With this integration, you can:
- Identify external opportunities to strengthen your pipeline
- Validate assumptions using competitive intelligence
- Monitor competitive activity and market shifts in real time
Let’s take a closer look at each one.
Identify External Opportunities to Strengthen Your Pipeline
Pipeline gaps are inevitable, but filling them has traditionally meant looking inward and force-fitting internal assets into those gaps — narrowing the field of options and increasing the risk of costly compromises, underperforming alternatives, or both.
With integrated external market intelligence, organizations gain visibility into both internal portfolio gaps and external opportunities to address them — understanding where their portfolio lacks coverage in key therapeutic areas, mechanisms of action, or development stages; and identifying potential acquisition targets that could fill those gaps. Additionally, teams can spot white-space opportunities where competition may be lighter or unmet needs remain significant.
This intelligence enables more strategic pipeline planning. Instead of discovering gaps and opportunities through reactive analysis, teams can proactively identify where their organization needs to strengthen coverage, which external assets could fill those gaps through acquisition or partnership, and where market conditions suggest the greatest potential for success.
Läs nästa: Pharmaceutical Portfolio Management: A Complete Primer
Validate Assumptions Using Competitive Intelligence
Every business case relies on assumptions about the probability of success, phase duration, trial design, and competitive positioning. But without reliable external data, those assumptions often go unvalidated until it’s too late to course-correct.
By benchmarking against similar clinical trials across the industry, teams can stress-test critical assumptions — such as failure rates and development timelines — against real-world evidence.
This capability transforms how organizations evaluate program viability. Decision-makers can compare their projections against comparable efforts across the industry — identifying assumptions that may be misaligned with actual market data earlier and building more defensible investment cases grounded in real-world evidence rather than internal estimates alone.
Läs nästa: 6 Criteria for Smarter, High-Impact Portfolio Investment Decisions
Monitor Competitive Activity and Market Shifts in Real Time
Competitive dynamics in pharma shift constantly. A competitor’s trial failure, a new mechanism entering Phase III, or a regulatory approval in an adjacent indication can all change the strategic value of programs in your portfolio — often before your next planning cycle.
By tracking competing products in development based on each project’s therapeutic profile, teams maintain a clear picture of the competitive context around every investment.
Rather than relying on periodic competitive reviews that quickly become outdated, Anvi proactively alerts teams when relevant competitor developments — such as delays, advances, or failures — could affect their forecasts. This allows teams to update assumptions as conditions change, so investment decisions reflect current market realities rather than a snapshot from last quarter.
Learn More with Planview
Ledarens guide till hantering av komplexa portföljer
Quick read · Actionable frameworks
When portfolio investments reach tens of millions or billions of dollars, uncertainty and complexity can stall even the most promising opportunities. This eBook shows you how to cut through the noise and prioritize with confidence.
